Protocol Ledger

NCT03212274 · Phase II · ACTIVE NOT RECRUITING

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

Interventional Phase II clinical trial protocol NCT03212274 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-01-30 Enrollment: 89 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03212274
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)89 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03212274
Protocol FieldVerified Registry Value
NCT IdentifierNCT03212274
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment89 participants (ACTUAL)
Registered Start Date2019-01-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI